Document resource
Lupus nephritis (LN) is the main organic manifestation of systemic lupus erythematosus (SLE). The earlier complete renal response (CRR) is achieved, the fewer nephrons are lost and the better long-term prognosis is expected. Methylprednisolone pulses (MP) have the potential to initiate rapid and mighty anti-inflammatory effects, facilitating the subsequent response to induction therapy. Whether MP should be generally used in patients with class III, IV and V LN would be the result of balancing their additional clinical efficacy and potential extra toxicity. In their thorough literature review, Gutowski and Belmont concluded that ‘the risks exceed the benefits for routine administration in all forms of LN’.1 Since my position is exactly the opposite (always talking about classes III, IV and V), I will try to explain why, basing my disagreement on the same evidence they compiled.